Tysabri makers report no new PML cases in drug evaluation

Share this article:
Biogen Idec and Elan announced that findings from their safety evaluation of the suspended drug Tysabri (natalizumab) in patients with Crohn's disease and rheumatoid arthritis, resulted in no new confirmed cases of the rare brain disease progressive multifocal leukoencephalopathy (PML).
 Both companies reported similarly positive results in August in a screening of nearly 2,000 sufferers of multiple sclerosis, who took the drug in clinical trials.
In their statement, Biogen and Elan said the safety evaluation into PML risks among patients in clinical trials is now complete.
Biogen and Elan voluntarily suspended Tysabri from the U.S. market in February after three confirmed cases of PML, two of which were fatal, were reported in patients taking the drug.
In a Wall Street Journal report, analysts said they expected a restricted return of Tysabri to the market in several months rather than in years.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.